Samatasvir

Samatasvir
Clinical data
Routes of; administration	Oral
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-((1R)-2-((2S)-2-(5-(4-(6-(2-((2S)-1-((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)pyrrolidin-2-yl)-3H-benzimidazol-5-yl)thieno(3,2-b)thiophen-3-yl)phenyl)-1H-imidazol-2-yl)pyrrolidin-1-yl)-2-oxo-1-phenylethyl)carbamate;
CAS Number	1312547-19-5;
PubChem CID	53302707;
ChemSpider	30843806;
UNII	21P699C5FC;
KEGG	D10665 ;
CompTox Dashboard (EPA)	DTXSID70156982 ;
Chemical and physical data
Formula	C47H48N8O6S2
Molar mass	885.07 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)[C@@H](C(=O)N1CCC[C@H]1c2[nH]c3ccc(cc3n2)c4csc5c4scc5c6ccc(cc6)c7c[nH]c(n7)[C@@H]8CCCN8C(=O)[C@@H](c9ccccc9)NC(=O)OC)NC(=O)OC;
	InChI InChI=1S/C47H48N8O6S2/c1-26(2)38(52-46(58)60-3)44(56)55-21-9-13-37(55)43-49-33-19-18-30(22-34(33)50-43)32-25-63-40-31(24-62-41(32)40)27-14-16-28(17-15-27)35-23-48-42(51-35)36-12-8-20-54(36)45(57)39(53-47(59)61-4)29-10-6-5-7-11-29/h5-7,10-11,14-19,22-26,36-39H,8-9,12-13,20-21H2,1-4H3,(H,48,51)(H,49,50)(H,52,58)(H,53,59)/t36-,37-,38-,39+/m0/s1; Key:ATOLIHZIXHZSBA-BTSKBWHGSA-N;

Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.^[1]

Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex.^[2] While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.^[3]

References

^ Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, et al. (May 2014). "A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4". Journal of Hepatology. 60 (5): 920–7. doi:10.1016/j.jhep.2014.01.003. PMID 24434503.
^ Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, et al. (August 2014). "In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus". Antimicrobial Agents and Chemotherapy. 58 (8): 4431–42. doi:10.1128/AAC.02777-13. PMC 4136001. PMID 24867983.
^ Clinical trial number NCT01852604 for "Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)" at ClinicalTrials.gov

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] Vince B, Hill JM, Lawitz EJ, O'Riordan W, Webster LR, Gruener DM, et al. (May 2014). "A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4". Journal of Hepatology. 60 (5): 920–7. doi:10.1016/j.jhep.2014.01.003. PMID 24434503.

[2] Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, et al. (August 2014). "In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus". Antimicrobial Agents and Chemotherapy. 58 (8): 4431–42. doi:10.1128/AAC.02777-13. PMC 4136001. PMID 24867983.

[3] Clinical trial number NCT01852604 for "Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)" at ClinicalTrials.gov

[1]

[2]

[3]

See also

References